8.52

4.67% 0.38

After Hours: 8.14 -0.38 -4.46%

Sagimet Biosciences Inc (SGMT)

Overview News Price History Discussions Forecast

Sagimet Biosciences Inc stock is traded at $8.52, with a volume of 314.79K. It is up +4.67% in the last 24 hours and up +24.20% over the past month. Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Previous Close:

$8.14

Open:

$8.14

24h Volume:

314.79K

Relative Volume:

0.54

Market Cap:

$264.13M

Revenue:

Net Income/Loss:

$-29.25M

P/E Ratio:

-7.1838

EPS:

-1.186

Net Cash Flow:

$-22.80M

1W Performance:

-6.78%

1M Performance:

+24.20%

6M Performance:

+146.96%

1Y Performance:

+65.44%

1-Day Range:

$8.14

$8.60

1-Week Range:

$8.02

$9.46

52-Week Range:

$1.73

$11.41

Sagimet Biosciences Inc Stock (SGMT) Company Profile

Name

Sagimet Biosciences Inc

Sector

Healthcare (1135)

Industry

Biotechnology (635)

Phone

(650) 561-8600

Address

155 BOVET RD., SUITE 303, SAN MATEO

Employee

Twitter

Next Earnings Date

Latest SEC Filings

SGMT's Discussions on Twitter

Compare SGMT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SGMT Sagimet Biosciences Inc	8.52	264.73M	0	-29.25M	-22.80M	-1.186
VRTX Vertex Pharmaceuticals Inc	425.57	107.66B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	651.80	68.74B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	456.04	58.93B	3.21B	43.57M	-52.09M	0.2405
ARGX Argen X Se Adr	818.50	50.51B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	189.60	41.29B	447.02M	-1.18B	-868.57M	-6.1812

Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-11-25	Initiated	Wedbush	Outperform
Aug-07-25	Resumed	H.C. Wainwright	Buy
Jul-24-25	Initiated	Canaccord Genuity	Buy
Dec-06-24	Initiated	Oppenheimer	Outperform
Nov-12-24	Initiated	UBS	Buy
Jun-28-24	Downgrade	Goldman	Buy → Neutral
May-02-24	Initiated	H.C. Wainwright	Buy
Mar-25-24	Initiated	Leerink Partners	Outperform
Aug-08-23	Initiated	Goldman	Buy
Aug-08-23	Initiated	JMP Securities	Mkt Outperform
Aug-08-23	Initiated	Piper Sandler	Overweight
Aug-08-23	Initiated	TD Cowen	Outperform

View All

Sagimet Biosciences Inc Stock (SGMT) Latest News

Nov 01, 2025